Lorven Therapeutics Private Limited - Due diligence report

A 360° intelligence report on Lorven Therapeutics Private Limited: trust score, financial health, credit view, compliance, directors, growth…

2017-10-18 Srikakulam, Andhra Pradesh Active Unlisted Active Non-Compliant
Share
Connect MCP
LT Lorven Therapeutics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Lorven Therapeutics Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
68/100
Trust Score
Moderate

Lorven Therapeutics Private Limited is assessed as Moderate with a Trust Score of 68/100. Lorven Therapeutics Private Limited is an active private limited indian non-government company incorporated in 2017, operating in the Business Outsourcing sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 21 Sep 2026 from the latest processed filings. Lorven Therapeutics Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
55/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 55/100 Moderate
  • Company status is Active as per MCA.
  • Marked ACTIVE non-compliant (INC-22A).
  • Last balance sheet is for Mar 2023 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 45/100
NameDIN / PANDesignationAppointedTenureDIN status
APPALANAIDU SATIPIDAKALA 01234567 Director 01/04/2018 6 yrs Approved
LAXMINARAYANA VANAPARTHI 01234567 Director 01/04/2018 6 yrs Approved
THAKASI VIJAYA KUMAR 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • THAKASI VIJAYA KUMAR has DIN status "Disqualified by RoC u/s 164(2)".
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 70
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
Statutory filings appear overdue.
Compliance score is weak (55/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence63/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view76/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 7 events
16 Oct 2023
Director ceased
VENKATARAMANA MUDILI
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
01 Oct 2021
Director appointed
APPALANAIDU SATIPIDAKALA (Additional Director)
Director appointed
LAXMINARAYANA VANAPARTHI (Additional Director)
18 Oct 2017
Incorporated
Registered with Roc Vijayawada
Director appointed
THAKASI VIJAYA KUMAR (Director)
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Rajebahadur Heart Foundation Private Limited U85110MH1999PTC119375 Nashik-422 001., Maharashtra, India
Ramdulari Healthcare Private Limited U85110UP2021PTC153359 Varanasi, Uttar Pradesh, India
Babu Ji Care Hospital Private Limited U85100CT2021PTC012474 Arang, Chattisgarh, India
Mahajan Diagnostics Private Limited U85110UP2005PTC030221 Bareilly, Uttar Pradesh, India
Avtar Surgical And Pharmaceuticals Private Limited U24233MH2021PTC369178 Nagpur, Maharashtra, India
People'S Medi-Treat Pvt Ltd U85110WB1995PTC076107 Howrah, West Bengal, India
Elawoman U74999DL2016PTC305834 New Delhi, Delhi, India
Lalit Memorial Hospital Private Limited U85190HR2022PTC100865 Jind, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Lorven Therapeutics Private Limited before audits and certifications: compliance score 55/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Lorven Therapeutics Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Lorven Therapeutics Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Lorven Therapeutics Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Lorven Therapeutics Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Lorven Therapeutics Private Limited an active company?

Lorven Therapeutics Private Limited has MCA status “Active” with a compliance score of 55/100 (Moderate).

Is Lorven Therapeutics Private Limited financially healthy?

Lorven Therapeutics Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Lorven Therapeutics Private Limited?

Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Lorven Therapeutics Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Lorven Therapeutics Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Lorven Therapeutics Private Limited up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 55/100 (Moderate).

Is it risky to lend to Lorven Therapeutics Private Limited?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.